Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update.

MLA

Eisen, Andrea, et al. “Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update.” Journal of Clinical Oncology, vol. 40, no. 7, Mar. 2022, pp. 787–800. EBSCOhost, https://doi.org/10.1200/JCO.21.02647.

APA

Eisen, A., Somerfield, M. R., Accordino, M. K., Blanchette, P. S., Clemons, M. J., Dhesy-Thind, S., Dillmon, M. S., D’Oronzo, S., Fletcher, G. G., Frank, E. S., Hallmeyer, S., Makhoul, I., Moy, B., Thawer, A., Wu, J. Y., & Van Poznak, C. H. (2022). Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update. Journal of Clinical Oncology, 40(7), 787–800. https://doi.org/10.1200/JCO.21.02647

Chicago

Eisen, Andrea, Mark R Somerfield, Melissa K Accordino, Phillip S Blanchette, Mark J Clemons, Sukhbinder Dhesy-Thind, Melissa S Dillmon, et al. 2022. “Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update.” Journal of Clinical Oncology 40 (7): 787–800. doi:10.1200/JCO.21.02647.